Drug Profile
Research programme: vaccines - Eyegene
Alternative Names: Influenza virus vaccine - Eyegene; Tuberculosis vaccine - EyegeneLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator EyeGene
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Tuberculosis
- Discontinued Influenza virus infections
Most Recent Events
- 28 Mar 2023 Preclinical development for Tuberculosis (Prevention) is ongoing in South Korea (Parenteral) (Eyegene pipeline, March 2023)
- 28 Mar 2023 Discontinued for Influenza virus infections (Prevention) in South Korea (Parenteral)
- 28 May 2018 No recent reports of development identified for preclinical development in Tuberculosis(Prevention) in South Korea (Parenteral)